Miscellaneous Malignancies | Norton Healthcare

Indication: Miscellaneous Malignancies

A First-in-human, Phase 1 Study to Evaluate the Safety of TTX-080, an HLA-G Antagonist, in Subjects with Advanced Solid Tumors

Sub-indication: Miscellaneous Malignancies

Drug Study

Principal Investigator: Jaspreet Grewal, M.D.
Norton Cancer Institute

Sponsor: Tizona Therapeutics, Inc.

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.